Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPFALAVIGNA, MaiconBELLI, Karlyse ClaudinoBARBOSA, Alexandre NaimeZAVASCKI, Alexandre PrehnNASTRI, Ana Catharina de Seixas SantosSANTANA, Christiane MachadoSTEIN, CinaraGRAF, Debora DalmasCADEGIANI, Flavio AdsuaraGUIMARAES, Helio PennaMONTEIRO, Jose TadeuFERREIRA, Juliana CarvalhoAZEVEDO, Luciano Cesar Pontes deMAGRI, Marcelo Mihailenko ChavesSOBREIRA, Marcone LimaDIAS, Maria Beatriz Gandra de SouzaOLIVEIRA, Maura Salaroli deCORRADI, Mirian de Freitas Dal BenROSA, RegisHEINZELMANN, Ricardo SouzaSILVA, Rosemeri Maurici daBELFORT JUNIOR, RubensCIMERMAN, SergioCOLPANI, VeronicaVEIGA, Viviane CordeiroCARVALHO, Carlos Roberto Ribeiro de2022-08-122022-08-122022BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, v.26, n.2, article ID 102347, 10p, 20221413-8670https://observatorio.fm.usp.br/handle/OPI/48348Background: Several therapies have been used or proposed for the treatment of COVID-19, although their effectiveness and safety have not been properly evaluated. The purpose of this document is to provide recommendations to support decisions about the drug treatment of outpatients with COVID-19 in Brazil.Methods: A panel consisting of experts from different clinical fields, representatives of the Brazilian Ministry of Health, and methodologists (37 members in total) was responsible for preparing these guidelines. A rapid guideline development method was used, based on the adoption and/or adaptation of recommendations from existing international guidelines combined with additional structured searches for primary studies and new recommendations whenever necessary (GRADE-ADOLOPMENT). The rating of quality of evidence and the drafting of recommendations followed the GRADE method.Results: Ten technologies were evaluated, and 10 recommendations were prepared. Recommendations were made against the use of anticoagulants, azithromycin, budesonide, colchicine, corticosteroids, hydroxychloroquine/chloroquine alone or combined with azithromycin, ivermectin, nitazoxanide, and convalescent plasma. It was not possible to make a recommendation regarding the use of monoclonal antibodies in outpatients, as their benefit is uncertain and their cost is high, with limitations of availability and implementation.Conclusion: To date, few therapies have demonstrated effectiveness in the treatment of outpatients with COVID-19. Recommendations are restricted to what should not be used, in order to provide the best treatment according to the principles of evidence-based medicine and to promote resource savings by aboiding ineffective treatments. (c) 2022 Sociedade Brasileira de Infectologia.engopenAccessCOVID-19COVID-19 drug treatmentGuidelineSARS-CoV-2BrazilGRADEarticleCopyright ELSEVIER BRAZIL10.1016/j.bjid.2022.102347Infectious Diseases1678-4391